Malik Kahook
Concepts (453)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 63 | 2025 | 242 | 14.580 |
Why?
| | Intraocular Pressure | 72 | 2025 | 315 | 9.740 |
Why?
| | Glaucoma, Open-Angle | 29 | 2024 | 104 | 6.570 |
Why?
| | Trabecular Meshwork | 23 | 2019 | 79 | 5.320 |
Why?
| | Glaucoma Drainage Implants | 18 | 2022 | 45 | 4.960 |
Why?
| | Antihypertensive Agents | 27 | 2019 | 508 | 4.440 |
Why?
| | Trabeculectomy | 17 | 2025 | 74 | 4.130 |
Why?
| | Preservatives, Pharmaceutical | 12 | 2024 | 26 | 3.840 |
Why?
| | Angiogenesis Inhibitors | 15 | 2021 | 229 | 3.570 |
Why?
| | Ocular Hypertension | 18 | 2024 | 67 | 3.440 |
Why?
| | Filtering Surgery | 9 | 2016 | 22 | 3.160 |
Why?
| | Conjunctiva | 13 | 2012 | 53 | 3.150 |
Why?
| | Ophthalmic Solutions | 18 | 2024 | 80 | 3.070 |
Why?
| | Benzalkonium Compounds | 11 | 2024 | 15 | 2.630 |
Why?
| | Tonometry, Ocular | 24 | 2025 | 103 | 2.450 |
Why?
| | Vascular Endothelial Growth Factor A | 12 | 2021 | 547 | 2.330 |
Why?
| | Phacoemulsification | 14 | 2025 | 120 | 2.290 |
Why?
| | Timolol | 8 | 2019 | 15 | 2.210 |
Why?
| | Prostaglandins F, Synthetic | 8 | 2014 | 9 | 2.200 |
Why?
| | Ciliary Body | 12 | 2025 | 40 | 2.060 |
Why?
| | Glaucoma, Neovascular | 5 | 2015 | 10 | 1.700 |
Why?
| | Cloprostenol | 9 | 2013 | 13 | 1.680 |
Why?
| | Laser Coagulation | 10 | 2025 | 71 | 1.600 |
Why?
| | Lens Implantation, Intraocular | 7 | 2020 | 67 | 1.360 |
Why?
| | Cataract Extraction | 6 | 2020 | 106 | 1.330 |
Why?
| | Cataract | 8 | 2020 | 223 | 1.320 |
Why?
| | Antibodies, Monoclonal | 11 | 2011 | 1456 | 1.300 |
Why?
| | Prosthesis Implantation | 8 | 2022 | 156 | 1.300 |
Why?
| | Optic Disk | 7 | 2025 | 52 | 1.270 |
Why?
| | Cornea | 8 | 2013 | 156 | 1.250 |
Why?
| | Tomography, Optical Coherence | 7 | 2025 | 258 | 1.250 |
Why?
| | Retinal Ganglion Cells | 6 | 2025 | 117 | 1.190 |
Why?
| | Drug Delivery Systems | 7 | 2019 | 361 | 1.190 |
Why?
| | Blister | 4 | 2012 | 40 | 1.170 |
Why?
| | Stents | 5 | 2021 | 535 | 1.120 |
Why?
| | Travoprost | 10 | 2014 | 13 | 1.110 |
Why?
| | Nerve Fibers | 4 | 2012 | 100 | 1.070 |
Why?
| | Medication Adherence | 4 | 2016 | 510 | 1.070 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 181 | 1.040 |
Why?
| | Optic Nerve Diseases | 3 | 2025 | 47 | 1.030 |
Why?
| | Humans | 135 | 2026 | 141284 | 1.020 |
Why?
| | Glaucoma, Angle-Closure | 5 | 2018 | 21 | 0.990 |
Why?
| | Sulfonamides | 4 | 2018 | 576 | 0.980 |
Why?
| | Endoscopy | 8 | 2025 | 327 | 0.980 |
Why?
| | Lenses, Intraocular | 4 | 2020 | 45 | 0.970 |
Why?
| | Corneal Diseases | 2 | 2024 | 45 | 0.960 |
Why?
| | Lens, Crystalline | 2 | 2020 | 133 | 0.950 |
Why?
| | Capsulorhexis | 2 | 2016 | 8 | 0.940 |
Why?
| | Polymers | 5 | 2011 | 494 | 0.900 |
Why?
| | Eye | 6 | 2013 | 113 | 0.900 |
Why?
| | Macular Degeneration | 4 | 2010 | 186 | 0.880 |
Why?
| | Photons | 4 | 2016 | 75 | 0.870 |
Why?
| | Microscopy | 4 | 2018 | 156 | 0.870 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2015 | 108 | 0.830 |
Why?
| | Dry Eye Syndromes | 1 | 2024 | 55 | 0.810 |
Why?
| | Pilocarpine | 2 | 2025 | 16 | 0.800 |
Why?
| | Vision Disorders | 4 | 2025 | 168 | 0.800 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2014 | 84 | 0.780 |
Why?
| | Cell Survival | 8 | 2013 | 1123 | 0.770 |
Why?
| | Aged | 45 | 2025 | 24836 | 0.750 |
Why?
| | Brimonidine Tartrate | 3 | 2018 | 10 | 0.750 |
Why?
| | Bevacizumab | 12 | 2021 | 135 | 0.730 |
Why?
| | Visual Acuity | 12 | 2025 | 449 | 0.720 |
Why?
| | Drug Packaging | 4 | 2015 | 43 | 0.720 |
Why?
| | Recombinant Fusion Proteins | 2 | 2015 | 672 | 0.700 |
Why?
| | Antibodies, Monoclonal, Humanized | 12 | 2011 | 908 | 0.680 |
Why?
| | Laser Therapy | 3 | 2016 | 128 | 0.670 |
Why?
| | Thiazines | 2 | 2018 | 13 | 0.670 |
Why?
| | Spectrum Analysis, Raman | 4 | 2013 | 42 | 0.650 |
Why?
| | Epithelium, Corneal | 2 | 2010 | 44 | 0.650 |
Why?
| | Visual Fields | 4 | 2025 | 117 | 0.650 |
Why?
| | Prosthesis Design | 4 | 2016 | 342 | 0.640 |
Why?
| | Thiophenes | 2 | 2011 | 128 | 0.630 |
Why?
| | Sclera | 7 | 2015 | 38 | 0.630 |
Why?
| | Drug Combinations | 9 | 2017 | 365 | 0.630 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 8 | 2016 | 67 | 0.620 |
Why?
| | beta-Alanine | 1 | 2019 | 22 | 0.590 |
Why?
| | Middle Aged | 43 | 2025 | 34658 | 0.590 |
Why?
| | Benzoates | 1 | 2019 | 49 | 0.590 |
Why?
| | Imaging, Three-Dimensional | 5 | 2016 | 565 | 0.580 |
Why?
| | Aged, 80 and over | 21 | 2025 | 7948 | 0.570 |
Why?
| | rho-Associated Kinases | 1 | 2019 | 81 | 0.560 |
Why?
| | Drug Monitoring | 3 | 2016 | 396 | 0.560 |
Why?
| | Ranibizumab | 8 | 2021 | 20 | 0.560 |
Why?
| | Cells, Cultured | 12 | 2015 | 4149 | 0.550 |
Why?
| | Ophthalmology | 5 | 2024 | 106 | 0.550 |
Why?
| | Ocular Hypotension | 4 | 2022 | 10 | 0.540 |
Why?
| | Male | 57 | 2025 | 70140 | 0.530 |
Why?
| | Treatment Outcome | 20 | 2025 | 11216 | 0.530 |
Why?
| | Retinal Pigment Epithelium | 4 | 2015 | 77 | 0.530 |
Why?
| | Prostaglandins F | 3 | 2011 | 16 | 0.520 |
Why?
| | Equipment Design | 6 | 2018 | 528 | 0.520 |
Why?
| | Anterior Capsule of the Lens | 1 | 2016 | 2 | 0.510 |
Why?
| | Epithelial Cells | 3 | 2011 | 1105 | 0.490 |
Why?
| | Retrospective Studies | 28 | 2025 | 16447 | 0.490 |
Why?
| | Patient Compliance | 4 | 2018 | 607 | 0.490 |
Why?
| | Prospective Studies | 14 | 2021 | 7805 | 0.480 |
Why?
| | Female | 54 | 2025 | 75814 | 0.480 |
Why?
| | Intravitreal Injections | 6 | 2021 | 60 | 0.470 |
Why?
| | Oxidative Stress | 2 | 2013 | 1327 | 0.460 |
Why?
| | Mitomycin | 3 | 2016 | 33 | 0.450 |
Why?
| | Wound Healing | 3 | 2012 | 349 | 0.450 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 202 | 0.450 |
Why?
| | Uveitis | 3 | 2022 | 148 | 0.450 |
Why?
| | Motivational Interviewing | 1 | 2016 | 118 | 0.440 |
Why?
| | Pharmaceutical Preparations | 2 | 2019 | 169 | 0.440 |
Why?
| | Reminder Systems | 1 | 2016 | 174 | 0.440 |
Why?
| | Circadian Rhythm | 3 | 2023 | 509 | 0.440 |
Why?
| | Iris | 4 | 2013 | 22 | 0.420 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5222 | 0.410 |
Why?
| | Injections | 6 | 2010 | 191 | 0.410 |
Why?
| | Behavior Therapy | 1 | 2016 | 282 | 0.410 |
Why?
| | Patient Preference | 1 | 2016 | 204 | 0.410 |
Why?
| | Pyruvates | 1 | 2013 | 24 | 0.400 |
Why?
| | Administration, Topical | 5 | 2016 | 150 | 0.400 |
Why?
| | Cell Count | 4 | 2021 | 319 | 0.400 |
Why?
| | Stainless Steel | 2 | 2010 | 22 | 0.400 |
Why?
| | Porphyrins | 1 | 2013 | 17 | 0.400 |
Why?
| | Pseudophakia | 2 | 2018 | 16 | 0.400 |
Why?
| | Triamcinolone Acetonide | 2 | 2014 | 19 | 0.390 |
Why?
| | Anterior Chamber | 2 | 2012 | 26 | 0.390 |
Why?
| | Perception | 3 | 2021 | 375 | 0.380 |
Why?
| | Goblet Cells | 2 | 2012 | 22 | 0.380 |
Why?
| | Photosensitizing Agents | 1 | 2013 | 42 | 0.380 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2026 | 768 | 0.380 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2011 | 2047 | 0.370 |
Why?
| | Health Behavior | 2 | 2015 | 784 | 0.370 |
Why?
| | Eye Diseases | 3 | 2024 | 93 | 0.370 |
Why?
| | Rabbits | 7 | 2015 | 664 | 0.370 |
Why?
| | Telemedicine | 1 | 2021 | 893 | 0.360 |
Why?
| | Drugs, Generic | 1 | 2011 | 25 | 0.360 |
Why?
| | Vitreous Body | 5 | 2010 | 122 | 0.350 |
Why?
| | Drug Therapy | 1 | 2011 | 81 | 0.350 |
Why?
| | Surgically-Created Structures | 1 | 2011 | 2 | 0.350 |
Why?
| | NADP | 1 | 2011 | 51 | 0.340 |
Why?
| | Adipocytes | 1 | 2012 | 220 | 0.340 |
Why?
| | Blood Pressure | 2 | 2017 | 1740 | 0.330 |
Why?
| | Fibrin Tissue Adhesive | 2 | 2010 | 20 | 0.330 |
Why?
| | Tissue Adhesives | 2 | 2010 | 23 | 0.330 |
Why?
| | Endothelins | 1 | 2010 | 63 | 0.320 |
Why?
| | Prescription Drugs | 1 | 2011 | 112 | 0.320 |
Why?
| | Choroid | 1 | 2010 | 78 | 0.320 |
Why?
| | Wet Macular Degeneration | 1 | 2010 | 57 | 0.310 |
Why?
| | Dexamethasone | 1 | 2012 | 375 | 0.310 |
Why?
| | Artificial Intelligence | 2 | 2025 | 342 | 0.300 |
Why?
| | Quinoxalines | 1 | 2009 | 67 | 0.300 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 334 | 0.300 |
Why?
| | Adult | 21 | 2025 | 39319 | 0.300 |
Why?
| | Depressive Disorder | 1 | 2012 | 375 | 0.290 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1059 | 0.290 |
Why?
| | Anti-Infective Agents | 1 | 2011 | 240 | 0.290 |
Why?
| | Anxiety Disorders | 1 | 2012 | 370 | 0.290 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2020 | 50 | 0.280 |
Why?
| | Surgical Wound Dehiscence | 1 | 2008 | 22 | 0.280 |
Why?
| | Collagen | 5 | 2016 | 452 | 0.280 |
Why?
| | Particulate Matter | 2 | 2011 | 330 | 0.280 |
Why?
| | Reproducibility of Results | 8 | 2025 | 3345 | 0.280 |
Why?
| | Primary Health Care | 2 | 2009 | 1757 | 0.280 |
Why?
| | Cognition Disorders | 1 | 2012 | 520 | 0.270 |
Why?
| | Aqueous Humor | 4 | 2016 | 38 | 0.270 |
Why?
| | Postoperative Period | 5 | 2025 | 359 | 0.270 |
Why?
| | Neovascularization, Pathologic | 4 | 2013 | 295 | 0.270 |
Why?
| | Software | 1 | 2012 | 675 | 0.260 |
Why?
| | Retinoschisis | 1 | 2006 | 2 | 0.260 |
Why?
| | Endothelium, Corneal | 2 | 2021 | 17 | 0.250 |
Why?
| | Fluorescence | 3 | 2011 | 161 | 0.250 |
Why?
| | Trypan Blue | 1 | 2006 | 6 | 0.250 |
Why?
| | Self Administration | 1 | 2007 | 124 | 0.250 |
Why?
| | Animals | 22 | 2016 | 37328 | 0.250 |
Why?
| | Carbohydrate Metabolism, Inborn Errors | 1 | 2006 | 2 | 0.240 |
Why?
| | Coloring Agents | 1 | 2006 | 96 | 0.240 |
Why?
| | Postoperative Complications | 7 | 2021 | 2831 | 0.240 |
Why?
| | Optic Nerve | 1 | 2006 | 66 | 0.240 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1395 | 0.240 |
Why?
| | Administration, Ophthalmic | 2 | 2019 | 16 | 0.240 |
Why?
| | Eye Injuries | 2 | 2006 | 53 | 0.240 |
Why?
| | Visual Field Tests | 2 | 2024 | 34 | 0.240 |
Why?
| | Iridectomy | 1 | 2005 | 1 | 0.240 |
Why?
| | Contact Lenses | 3 | 2020 | 11 | 0.240 |
Why?
| | Retinal Degeneration | 1 | 2006 | 38 | 0.230 |
Why?
| | Pseudotumor Cerebri | 1 | 2006 | 31 | 0.230 |
Why?
| | Acrylic Resins | 2 | 2016 | 47 | 0.230 |
Why?
| | Monitoring, Physiologic | 2 | 2018 | 287 | 0.230 |
Why?
| | Histological Techniques | 2 | 2018 | 39 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2016 | 534 | 0.230 |
Why?
| | Visual Pathways | 1 | 2025 | 59 | 0.220 |
Why?
| | Cadaver | 3 | 2016 | 305 | 0.220 |
Why?
| | Pilot Projects | 5 | 2018 | 1820 | 0.210 |
Why?
| | Alkylating Agents | 3 | 2016 | 24 | 0.210 |
Why?
| | United States Food and Drug Administration | 2 | 2015 | 197 | 0.210 |
Why?
| | Retina | 3 | 2016 | 314 | 0.200 |
Why?
| | Case-Control Studies | 5 | 2024 | 3577 | 0.200 |
Why?
| | Surveys and Questionnaires | 6 | 2022 | 5948 | 0.190 |
Why?
| | Drug Stability | 3 | 2011 | 165 | 0.190 |
Why?
| | Prostaglandins, Synthetic | 2 | 2013 | 5 | 0.190 |
Why?
| | Titanium | 2 | 2014 | 85 | 0.190 |
Why?
| | ROC Curve | 1 | 2024 | 594 | 0.190 |
Why?
| | Wounds, Nonpenetrating | 1 | 2005 | 309 | 0.180 |
Why?
| | Nervous System Diseases | 1 | 2024 | 278 | 0.180 |
Why?
| | Heart Rate | 2 | 2017 | 835 | 0.170 |
Why?
| | Drug Storage | 2 | 2011 | 53 | 0.170 |
Why?
| | Self Report | 2 | 2016 | 859 | 0.170 |
Why?
| | Cross-Sectional Studies | 7 | 2022 | 5653 | 0.170 |
Why?
| | Young Adult | 8 | 2019 | 13727 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2020 | 80 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 130 | 0.150 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 20 | 0.150 |
Why?
| | Attitude | 1 | 2021 | 257 | 0.150 |
Why?
| | Postoperative Care | 3 | 2025 | 280 | 0.140 |
Why?
| | Limbus Corneae | 2 | 2015 | 8 | 0.140 |
Why?
| | Biosensing Techniques | 1 | 2020 | 138 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 124 | 0.140 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 24 | 0.140 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3734 | 0.140 |
Why?
| | Medication Errors | 2 | 2015 | 97 | 0.140 |
Why?
| | Fibroblasts | 2 | 2013 | 1018 | 0.130 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2019 | 227 | 0.130 |
Why?
| | Double-Blind Method | 2 | 2019 | 1992 | 0.130 |
Why?
| | Tropicamide | 1 | 2016 | 2 | 0.130 |
Why?
| | Mydriatics | 1 | 2016 | 9 | 0.130 |
Why?
| | Phenylephrine | 1 | 2016 | 75 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 262 | 0.130 |
Why?
| | Marijuana Use | 1 | 2020 | 221 | 0.120 |
Why?
| | Delayed-Action Preparations | 2 | 2018 | 175 | 0.120 |
Why?
| | Endophthalmitis | 1 | 2016 | 45 | 0.120 |
Why?
| | Fibrosis | 1 | 2018 | 541 | 0.120 |
Why?
| | Artificial Lens Implant Migration | 1 | 2015 | 3 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 458 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 716 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 634 | 0.120 |
Why?
| | Hyaluronic Acid | 2 | 2008 | 227 | 0.120 |
Why?
| | Swine | 3 | 2013 | 821 | 0.110 |
Why?
| | Alloys | 1 | 2015 | 38 | 0.110 |
Why?
| | Endothelial Cells | 1 | 2021 | 816 | 0.110 |
Why?
| | Surgical Flaps | 1 | 2016 | 144 | 0.110 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1243 | 0.110 |
Why?
| | Capsule Opacification | 1 | 2015 | 22 | 0.110 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 12 | 0.110 |
Why?
| | Biodegradable Plastics | 1 | 2014 | 3 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2023 | 1078 | 0.110 |
Why?
| | Endpoint Determination | 1 | 2015 | 77 | 0.110 |
Why?
| | Micelles | 1 | 2014 | 39 | 0.110 |
Why?
| | Viscosupplements | 1 | 2014 | 11 | 0.110 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1043 | 0.110 |
Why?
| | Nickel | 1 | 2014 | 61 | 0.100 |
Why?
| | Cell Proliferation | 2 | 2012 | 2502 | 0.100 |
Why?
| | Autopsy | 2 | 2011 | 98 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 2 | 2018 | 874 | 0.100 |
Why?
| | Societies, Medical | 2 | 2015 | 859 | 0.100 |
Why?
| | Disease Progression | 3 | 2024 | 2808 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2019 | 802 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 350 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 930 | 0.100 |
Why?
| | Drug Synergism | 1 | 2014 | 367 | 0.100 |
Why?
| | Gonioscopy | 1 | 2013 | 11 | 0.100 |
Why?
| | Models, Psychological | 1 | 2015 | 312 | 0.100 |
Why?
| | Protective Agents | 1 | 2013 | 41 | 0.100 |
Why?
| | Tissue Scaffolds | 1 | 2015 | 213 | 0.100 |
Why?
| | Macular Edema | 2 | 2016 | 46 | 0.100 |
Why?
| | Neuroprotective Agents | 1 | 2014 | 142 | 0.100 |
Why?
| | Antimetabolites | 1 | 2012 | 21 | 0.100 |
Why?
| | Photochemotherapy | 1 | 2013 | 39 | 0.100 |
Why?
| | Manifest Anxiety Scale | 1 | 2012 | 4 | 0.090 |
Why?
| | Patient Satisfaction | 1 | 2016 | 695 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1655 | 0.090 |
Why?
| | Quality of Life | 1 | 2024 | 3024 | 0.090 |
Why?
| | Cross-Over Studies | 1 | 2014 | 578 | 0.090 |
Why?
| | Melanins | 1 | 2011 | 17 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 51 | 0.090 |
Why?
| | Elastin | 1 | 2011 | 79 | 0.090 |
Why?
| | Needles | 1 | 2012 | 63 | 0.090 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 329 | 0.090 |
Why?
| | Fluoresceins | 1 | 2011 | 47 | 0.090 |
Why?
| | Cattle | 1 | 2014 | 982 | 0.090 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2011 | 35 | 0.090 |
Why?
| | Self Efficacy | 1 | 2015 | 404 | 0.090 |
Why?
| | Biocompatible Materials | 1 | 2015 | 431 | 0.090 |
Why?
| | Cell Death | 1 | 2013 | 386 | 0.090 |
Why?
| | Lasers | 1 | 2011 | 129 | 0.080 |
Why?
| | Dextrans | 1 | 2011 | 85 | 0.080 |
Why?
| | Psychometrics | 1 | 2015 | 736 | 0.080 |
Why?
| | Memory Disorders | 1 | 2012 | 183 | 0.080 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 133 | 0.080 |
Why?
| | Immunoglobulin Fragments | 1 | 2010 | 11 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 1 | 2014 | 477 | 0.080 |
Why?
| | Silicone Oils | 1 | 2011 | 32 | 0.080 |
Why?
| | Fovea Centralis | 1 | 2010 | 23 | 0.080 |
Why?
| | Retreatment | 1 | 2010 | 74 | 0.080 |
Why?
| | Equipment Safety | 1 | 2010 | 35 | 0.080 |
Why?
| | Physician-Patient Relations | 1 | 2015 | 579 | 0.080 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 38 | 0.080 |
Why?
| | Microscopy, Electron, Scanning | 4 | 2015 | 202 | 0.080 |
Why?
| | Chromatography, Gel | 1 | 2010 | 128 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2012 | 225 | 0.080 |
Why?
| | Immunoglobulin Light Chains | 1 | 2010 | 51 | 0.080 |
Why?
| | Torque | 1 | 2010 | 80 | 0.080 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2010 | 85 | 0.080 |
Why?
| | Motivation | 1 | 2015 | 600 | 0.080 |
Why?
| | Molecular Weight | 1 | 2010 | 326 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2016 | 5866 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 194 | 0.080 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 333 | 0.080 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2010 | 81 | 0.080 |
Why?
| | Aptamers, Nucleotide | 1 | 2010 | 85 | 0.080 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 35 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 589 | 0.080 |
Why?
| | Tissue Donors | 1 | 2012 | 406 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 309 | 0.080 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 321 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2010 | 324 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 803 | 0.070 |
Why?
| | Suture Techniques | 1 | 2010 | 129 | 0.070 |
Why?
| | Risk Assessment | 2 | 2020 | 3522 | 0.070 |
Why?
| | Sodium Chloride | 1 | 2009 | 140 | 0.070 |
Why?
| | Communication | 1 | 2015 | 941 | 0.070 |
Why?
| | Vasoconstriction | 1 | 2010 | 215 | 0.070 |
Why?
| | Ocular Motility Disorders | 1 | 2009 | 33 | 0.070 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 415 | 0.070 |
Why?
| | Amphetamine-Related Disorders | 1 | 2009 | 45 | 0.070 |
Why?
| | Choroidal Neovascularization | 1 | 2009 | 57 | 0.070 |
Why?
| | Retinal Vein Occlusion | 1 | 2008 | 13 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2011 | 565 | 0.070 |
Why?
| | Chondroitin | 1 | 2008 | 6 | 0.070 |
Why?
| | Fluorescein | 1 | 2008 | 23 | 0.070 |
Why?
| | Risk Factors | 3 | 2018 | 10490 | 0.070 |
Why?
| | Methamphetamine | 1 | 2009 | 67 | 0.070 |
Why?
| | Microvilli | 1 | 2008 | 75 | 0.070 |
Why?
| | Rupture | 1 | 2008 | 88 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 849 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2010 | 910 | 0.070 |
Why?
| | Lymphocyte Count | 1 | 2008 | 167 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 855 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 181 | 0.070 |
Why?
| | Time Factors | 3 | 2019 | 6951 | 0.070 |
Why?
| | Neuropsychological Tests | 1 | 2012 | 1090 | 0.070 |
Why?
| | Cell Line | 1 | 2013 | 2863 | 0.070 |
Why?
| | Mice | 6 | 2016 | 17969 | 0.070 |
Why?
| | Central Nervous System Stimulants | 1 | 2009 | 178 | 0.070 |
Why?
| | Mice, Inbred BALB C | 3 | 2015 | 1261 | 0.060 |
Why?
| | United States | 5 | 2022 | 15298 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2840 | 0.060 |
Why?
| | Molteno Implants | 1 | 2006 | 2 | 0.060 |
Why?
| | Perioperative Care | 2 | 2019 | 228 | 0.060 |
Why?
| | Uveal Diseases | 1 | 2006 | 6 | 0.060 |
Why?
| | Conjunctivitis | 1 | 2006 | 31 | 0.060 |
Why?
| | Glucosyltransferases | 1 | 2006 | 4 | 0.060 |
Why?
| | Sutures | 1 | 2006 | 60 | 0.060 |
Why?
| | Scleral Buckling | 1 | 2006 | 18 | 0.060 |
Why?
| | Sweat Gland Neoplasms | 1 | 2006 | 8 | 0.060 |
Why?
| | Eyelid Neoplasms | 1 | 2006 | 10 | 0.060 |
Why?
| | Lymphocytes | 1 | 2008 | 390 | 0.060 |
Why?
| | Motorcycles | 1 | 2005 | 7 | 0.060 |
Why?
| | Geniculate Bodies | 1 | 2025 | 20 | 0.060 |
Why?
| | Glycosylation | 1 | 2006 | 162 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 15 | 0.060 |
Why?
| | Fundus Oculi | 1 | 2025 | 86 | 0.060 |
Why?
| | Uncertainty | 1 | 2026 | 137 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1973 | 0.060 |
Why?
| | Forecasting | 1 | 2007 | 383 | 0.060 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2006 | 76 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2795 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 376 | 0.060 |
Why?
| | Treatment Failure | 1 | 2006 | 355 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2023 | 2069 | 0.050 |
Why?
| | Vietnam | 1 | 2023 | 27 | 0.050 |
Why?
| | Accidents, Traffic | 1 | 2005 | 191 | 0.050 |
Why?
| | Sleep | 2 | 2023 | 882 | 0.050 |
Why?
| | Materials Testing | 2 | 2015 | 354 | 0.050 |
Why?
| | Optical Imaging | 2 | 2015 | 64 | 0.050 |
Why?
| | Incidence | 1 | 2010 | 2809 | 0.050 |
Why?
| | Area Under Curve | 1 | 2024 | 324 | 0.050 |
Why?
| | Neurology | 1 | 2024 | 112 | 0.050 |
Why?
| | Injections, Intraocular | 2 | 2014 | 13 | 0.050 |
Why?
| | Photography | 1 | 2023 | 114 | 0.050 |
Why?
| | Reoperation | 1 | 2006 | 599 | 0.050 |
Why?
| | Sex Factors | 1 | 2009 | 2055 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2487 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2007 | 1035 | 0.050 |
Why?
| | Age Factors | 1 | 2009 | 3295 | 0.040 |
Why?
| | Manometry | 1 | 2021 | 97 | 0.040 |
Why?
| | Prognosis | 2 | 2020 | 4080 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 316 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2006 | 1144 | 0.040 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2018 | 14 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 143 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2018 | 16 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| | Drug Resistance | 1 | 2018 | 149 | 0.030 |
Why?
| | Adolescent | 4 | 2019 | 22116 | 0.030 |
Why?
| | Refraction, Ocular | 1 | 2018 | 43 | 0.030 |
Why?
| | Pupil | 1 | 2016 | 22 | 0.030 |
Why?
| | Rats | 2 | 2016 | 5556 | 0.030 |
Why?
| | Biomimetics | 1 | 2016 | 43 | 0.030 |
Why?
| | Nerve Regeneration | 1 | 2016 | 58 | 0.030 |
Why?
| | Neurites | 1 | 2016 | 51 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2016 | 43 | 0.030 |
Why?
| | Prednisolone | 1 | 2016 | 68 | 0.030 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.030 |
Why?
| | Slit Lamp | 1 | 2015 | 3 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 69 | 0.030 |
Why?
| | Opossums | 1 | 2015 | 9 | 0.030 |
Why?
| | Medical Device Legislation | 1 | 2015 | 2 | 0.030 |
Why?
| | Device Approval | 1 | 2015 | 17 | 0.030 |
Why?
| | Anterior Eye Segment | 1 | 2015 | 11 | 0.030 |
Why?
| | Color | 1 | 2015 | 81 | 0.030 |
Why?
| | Muscle, Smooth | 1 | 2016 | 150 | 0.030 |
Why?
| | Academies and Institutes | 1 | 2015 | 54 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2015 | 122 | 0.030 |
Why?
| | Axons | 1 | 2016 | 198 | 0.030 |
Why?
| | Device Removal | 1 | 2016 | 141 | 0.030 |
Why?
| | Validation Studies as Topic | 1 | 2014 | 22 | 0.030 |
Why?
| | Membrane Lipids | 1 | 2015 | 82 | 0.030 |
Why?
| | Drug Utilization | 1 | 2015 | 166 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 4006 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 2015 | 96 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 391 | 0.030 |
Why?
| | Quality Control | 1 | 2014 | 160 | 0.030 |
Why?
| | Reference Standards | 1 | 2014 | 180 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 191 | 0.030 |
Why?
| | Corneal Stroma | 1 | 2013 | 25 | 0.030 |
Why?
| | Photoreceptor Cells, Vertebrate | 1 | 2013 | 25 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2013 | 80 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2013 | 152 | 0.020 |
Why?
| | Finite Element Analysis | 1 | 2012 | 75 | 0.020 |
Why?
| | Biological Availability | 1 | 2012 | 137 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 522 | 0.020 |
Why?
| | Permeability | 1 | 2012 | 163 | 0.020 |
Why?
| | Attitude to Health | 1 | 2015 | 451 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2012 | 165 | 0.020 |
Why?
| | Chronic Disease | 2 | 2008 | 1807 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 669 | 0.020 |
Why?
| | Massage | 1 | 2011 | 42 | 0.020 |
Why?
| | Drug Compounding | 1 | 2011 | 104 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2009 | 14 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2012 | 487 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 403 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5809 | 0.020 |
Why?
| | Ultrasonography | 1 | 2011 | 765 | 0.020 |
Why?
| | Pigment Epithelium of Eye | 1 | 2006 | 36 | 0.020 |
Why?
| | Mohs Surgery | 1 | 2006 | 28 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1866 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2006 | 217 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2006 | 771 | 0.010 |
Why?
| | Biomarkers | 1 | 2015 | 4180 | 0.010 |
Why?
| | Biopsy | 1 | 2006 | 1073 | 0.010 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2009 | 656 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2006 | 1491 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 7035 | 0.010 |
Why?
| | Infant | 1 | 2010 | 9820 | 0.010 |
Why?
| | Child, Preschool | 1 | 2010 | 11511 | 0.010 |
Why?
| | Child | 1 | 2010 | 22390 | 0.000 |
Why?
|
|
Kahook's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|